Pharmacy benefit management company Catamaran announced Thursday it has entered into an agreement to acquire its smaller rival Restat for $409.5 million. Catamaran, which also specializes in pharmaceutical technologies and services, described the deal as a “great opportunity” for the company, as Restat, which is one of the largest private PBM companies and also provides claim processing services, has a core business that “aligns perfectly” with Catamaran’s. Catamaran manages prescriptions for 25 million members.
Featured News
Croatia Competition Authority Approves HPB Acquisition of Croatia Banka
Jul 19, 2026 by
CPI
Democratic Lawmakers Urge DOJ to Closely Examine Fox-Roku Merger
Jul 19, 2026 by
CPI
US Judge Clears Path for Broad Beef Antitrust Class Actions Against Major Meatpackers
Jul 19, 2026 by
CPI
India’s Competition Regulator Dismisses Antitrust Complaint Against Reliance Jio and 4,500 Firms
Jul 19, 2026 by
CPI
Apple Opens Early Settlement Discussions With DOJ
Jul 17, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Agentic AI & Antitrust
Jul 16, 2026 by
CPI
AI Agents and Collusion: The Two Faces of Agentic AI
Jul 16, 2026 by
Giovanna Massarotto
Agentic AI’s Regulatory Conundrum
Jul 16, 2026 by
Anant Raut
Inter-AI-Agent Competition
Jul 16, 2026 by
Stefan Thomas
Navigating the Increasing Regulatory Scrutiny of AI-Pricing Tools: Competition and Other Emerging Risks
Jul 16, 2026 by
Mark Krotoski & Vinny Sidhu